Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2014  |  Volume : 10  |  Issue : 4  |  Page : 1107-1108

Newly diagnosed breast cancer in a patient receiving imatinib mesylate

1 Department of Internal Medicine, Divisions of Hematology, Marmara University Hospital, Istanbul, Turkey
2 Department of Internal Medicine, Divisions of Medical Oncology, Marmara University Hospital, Istanbul, Turkey

Correspondence Address:
Tayfur Toptas
Marmara University Pendik Training and Research Hospital, Fevzi Cakmak Mah. Muhsin Yazicioglu Cad. No: 10, Ust Kaynarca, Pendik, Istanbul
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.146095

Rights and Permissions

Imatinib mesylate is the standard treatment of chronic myeloid leukemia (CML). Despite imatinib is being used in the treatment of other malignancies as well, its potential role on de novo tumor growth is not known. Secondary malignancies are rarely seen in patients with CML and particularly in those receiving imatinib. Here, we present a CML patient taking imatinib therapy that was diagnosed to have breast cancer and received adjuvant chemo-and radiotherapy with imatinib. We tried to explain co-occurrence of these rare events by probable pathogenetic mechanisms.

Abstract in Chinese

新诊断的乳腺癌患者接受甲磺酸伊马替尼治疗 摘要 甲磺酸伊马替尼是慢性髓性白血病(CML)的标准治疗。尽管伊马替尼用于治疗其他恶性肿瘤,其在新发肿瘤生长中的潜在作用是不知道的。继发的恶性肿瘤中很少见到,特别是在慢性粒细胞白血病患者接受伊马替尼后。在这里,我们介绍一例服用伊马替尼治疗的CML患者,被诊断患有乳腺癌并接受辅助化疗、放疗和伊马替尼治疗。我们试图以可能的发病机制,解释这些罕见的事件发生。 关键词:乳腺癌,慢性粒细胞白血病,伊马替尼

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded121    
    Comments [Add]    

Recommend this journal